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BACKGROUND: Genetic changes have been widely reported in association with cholangiocarcinoma (CCA), while epigenetic changes
are poorly characterised. We aimed to further evaluate CpG-island hypermethylation in CCA at candidate loci, which may have
potential as diagnostic or prognostic biomarkers.
METHODS: We analysed methylation of 26 CpG-islands in 102 liver fluke related-CCA and 29 adjacent normal samples using
methylation-specific PCR (MSP). Methylation of interest loci was confirmed using pyrosequencing and/or combined bisulfite
restriction analysis, and protein expression by immunohistochemistry.
RESULTS: A number of CpG-islands (OPCML, SFRP1, HIC1, PTEN and DcR1) showed frequency of hypermethylation in 428% of CCA,
but not adjacent normal tissues. The results showed that 91% of CCA were methylated in at least one CpG-island. The OPCML was
the most frequently methylated locus (72.5%) and was more frequently methylated in less differentiated CCA. Patients with
methylated DcR1 had significantly longer overall survival (Median; 41.7 vs 21.7 weeks, P¼0.027). Low-protein expression was found
in 470% of CCA with methylation of OPCML or DcR1.
CONCLUSION: Aberrant hypermethylation of certain loci is a common event in liver fluke-related CCA and may potentially contribute
to cholangiocarcinogenesis. The OPCML and DcR1 might serve as methylation biomarkers in CCA that can be readily examined
by MSP.
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Cholangiocarcinoma (CCA), a malignancy originating from biliary
epithelium, has been considered as a rare disease, which globally
accounts for 10–25% of primary liver cancers (Kamangar et al,
2006). As the incidence and mortality rates for intrahepatic CCA
(ICC) have markedly increased worldwide (Patel, 2002; Khan et al,
2005), there has been growing interest in this cancer. Cholangio-
carcinoma represents a major public health problem in Thailand,
particularly in the northeast region where Opisthorchis viverrini
(OV) infection remains highly endemic. The prevalence of OV
infection in this region is 15.7%, while the average in Khon Kaen
(the centre for CCA collection in the present study) is 24.5% (Sripa
et al, 2007). Here, CCA accounts for the highest incidence
worldwide with truncated age-standardised incidence of ages
435 years up to 317.6 per 100000 population (Sriamporn et al,
2004). Infection with OV occurs when raw or undercooked
cyprinoid fish with the infective stage of metacercariae is ingested
(Sripa et al, 2007). However, OV infection alone does not cause
CCA. Animal experiments suggest that OV infection in combination
with nitrosamine administration is the causation of CCA in a dose-
dependent manner (Thamavit et al, 1978, 1987). Honjo et al (2005)
conducted a population-based case–control study on genetic and
environmental risk factors for OV-related CCA. They showed that
anti-OV antibody X0.200 was the strongest risk indicator.
Furthermore, dietary habits during the past 10 years, raw fish
intake (OV infection) and fermented fish or pork intake
(exogenous nitrosamine) were significantly associated with an
increased risk. Alcohol drinking, but not smoking showed a higher
risk in which alcohol may affect metabolic pathways of endogenous
and exogenous nitrosamines. The prognosis of CCA is generally poor
with o5% of patients surviving 45 years and has not significantly
improved over the past three decades (Shaib and El-Serag, 2004). This
can partly be attributed to the factt h a tC C Ai sd i f f i c u l tt od i a g n o s e
and often presents at a late clinical stage. Biomarkers, which allow
earlier detection of CCA could potentially impact on patient survival
by allowing earlier treatment. Although surgical resection can be
potentially curative, only a few patients are suitable for surgery
because of spread of the disease when late presenting, and effective
non-surgical therapies are limited (Patel, 2006).
Epidemiological and experimental evidence implicate the
carcinogenic liver fluke as a major risk factor of CCA. It is
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spossible that chronic inflammation driven by the infection makes
the biliary epithelium more susceptible to neoplastic transforma-
tion. (Thamavit et al, 1978; IARC, 1994). However, the exact
molecular events involved in cholangiocarcinogenesis are not well
understood. Like other tumours, CCA is a result of a multistep
process in which genetic and epigenetic aberrations of regulatory
genes are accumulated. For instance, genetic alterations of K-ras
(Ohashi et al, 1995) and p53 (Limpaiboon et al, 2002; Liu et al,
2006b) have frequently been reported in CCA. Aberrant DNA
methylation at CpG-islands associated with transcriptional silen-
cing is widely observed in cancers (Esteller, 2006). DNA
methylation is a potential rich source of diagnostic, prognostic
or predictive biomarkers of clinical outcome. Hypermethylation in
CCA has been reported in tumour suppressor genes related to cell
cycle (p16, 14–3–3s, p73, p14, p15), apoptosis (DAPK, SEMA3B)
and cell adhesion (APC, E-cadherin, TIMP3, THBS1) (Lee et al,
2002; Tannapfel et al, 2002; Tischoff et al, 2005; Yang et al, 2005;
Chinnasri et al, 2009). Furthermore, several reports demonstrated
hypermethylation of genes involved in DNA repair and carcinogen
metabolism, such as hMLH1, MGMT and GSTP1 (Lee et al, 2002;
Limpaiboon et al, 2005; Yang et al, 2005). However, while these
previous studies have reported aberrant methylation at several loci
in CCA, their evaluation as diagnostic or prognostic biomarkers is
still limited.
To further elucidate the role of methylation in liver fluke-related
CCA, we here analysed the methylation status by methylation-
specific PCR (MSP) of a defined set of 26 CpG islands at genes,
which function in cell cycle, apoptosis, DNA repair and cell–cell
interaction, which have been previously reported in CCA and other
types of cancer as frequently methylated. Methylation-specific PCR
was performed in 102 primary CCA and where possible adjacent
normal tissues. Methylation-specific PCR provides a relatively
simple and cost-effective assay that can be used to assess
methylation in clinical samples, however, for loci of interest, we
have confirmed methylation status by bisulfite pyrosequencing or
combined bisulfite restriction analysis (COBRA). We have identified
differential hypermethylation of a number of CpG-islands and
reported the associations to clinicopathological parameters.
MATERIALS AND METHODS
Samples and clinicopathological data
Frozen tissues of 102 primary CCA and 29 tumour-adjacent
normal samples were used. Moreover, those CCA samples, which
had paraffin-embedded sections were also used for immuno-
histochemistry. Clinicopathological data of CCA patients, includ-
ing age at initial diagnosis, gender, gross types, histological grades
and the overall survival time (excluding patients who died within
4 weeks after surgery) were also collected. All of the samples and
data were kindly supplied by the Liver Fluke and Cholangiocarci-
noma Research Centre, Khon Kaen University (Khon Kaen,
Thailand). Among CCA samples, mean age at initial diagnosis
was 55 years (45.2–64.8 years), and 68 males and 34 females were
accounted. Cholangiocarcinoma samples were classified into three
gross types; mass forming (MF, n¼65), periductal infiltrating
(PI, n¼26) and intraductal growth (ID, n¼11) type, and two
histological grades; well differentiated (n¼74) and less differ-
entiated (included moderate and poor differentiation, n¼25).
Median overall survival time of CCA patients was 29 weeks. The
study was reviewed and approved by the Khon Kaen University
Ethics Committee for Human Research (HE510651).
DNA extraction and bisulfite modification
Genomic DNA was extracted from frozen liver tissues using
DNeasy Tissue Kit (Qiagen, Hercules, CA, USA) according to the
manufacturer’s protocols. Genomic DNA (1mg) from each sample
was modified by sodium bisulfite as described by Herman et al
(1996) with slight modification as previously reported (Sriraksa
et al, 2010). The quality of bisulfite-converted DNA was verified
by PCR amplification using Calponin-specific primer sets as
previously described (Teodoridis et al, 2005; Sriraksa et al, 2010).
Methylation-specific PCR (MSP)
Methylated-specific primers and PCR conditions of 22 CpG-islands
for MSP were obtained from methprimerDB (http://medgen.
ugent.be/methprimerdb/index.php). In addition, the methylated-
specific primers and PCR conditions for 14–3–3s, DcR2, DR4 and
DR5 were obtained from previous studies (Lee et al, 2002;
van Noesel et al, 2002; Liu et al, 2008). Methylation-specific PCR
(25ml per reaction) was performed on a PTC-100 Thermal cycle
(MJ Research INC., Ramsey, MN, USA) as the appropriate PCR
conditions for each locus. Methylation-positive sample was defined
by comparing the MSP product to those of diluted in vitro
methyltransferase-treated placental DNA (positive control) and the
weak signal was disregarded.
Pyrosequencing
Pyrosequencing of bisulfite modified DNA was used to validate
methylation status of candidate loci, OPCML and DcR1, previously
identified by MSP. The primers for OPCML amplification and
sequencing were; 50-GGGAGTGTGAGATGTATGTGAGTG-30 (for-
ward), 50-biotin-TACCCCCAAAACCACAACTAATT-30 (reverse) and
50-AGAGGTAGGTTTGTTGTGT-30 (sequencing) and for DcR1;
50-TTGGTAGTGTAGTTGTGGGAATTTTT-30 (forward), 50-biotin-TCT
ATCCCCAAAATTCCCTAA-30 (reverse) and 50-GGTAGTGTAGTTGT
GGGAA-30 (sequencing). The schematics of these specific primers for
pyrosequencing are shown in Supplementary Figure 1, upper and
lower panels. DNA used as a template of PCR was bisulfite modified
using EpiTect Bisulfite Kit (Qiagen, West Sussex, UK), and the
annealing temperature and MgCl2 concentration for OPCML and
DcR1 were 631C, 2mM and 611C, 3.6mM, respectively. Pyrosequen-
cing of PCR products was performed using PyroGold Reagent kit
(Biotage, Uppsala, Sweden) according to the manufacturer’s instruc-
tion. The methylation percentage at individual CpG sites was then
analysed using the Pyro Q-CpG software (Biotage).
Combined bisulfite restriction analysis (COBRA)
COBRA was performed to validate methylation status of OPCML,
for which specific primers, amplification condition and restriction
enzyme used were obtained from methprimerDB (http://medgen.
ugent.be/methprimerdb/index.php). The positions of OPCML-
specific primers for COBRA were located in the same region as
for MSP (Supplementary Figure 1, upper panel). Digestion was
performed by incubation at 371C for 2h, before separation on a
2% agarose gel in which band intensity and methylation level were
evaluated.
Immunohistochemistry
The expression of OPCML and DcR1 was examined in formalin
fixed paraffin-embedded tissue sections of primary CCA using
immunohistochemistry as previously described (Hussain et al,
2010). Antigen retrieval was performed by microwave heating in
EDTA (pH 9.0) for 20min. To block non-specific antibody
binding, sections were incubated with 2.5% normal horse serum
(Vector Laboratories, Peterborough, UK) for 10min. Here,
sections were incubated overnight at 41C with OPCML monoclonal
mouse antibody (1:1000 dilution; Anti-human OBCAM:
MAB27771, R&D Systems, Abingdon, UK) or DcR1 monoclonal
mouse antibody (1:100 dilution; DcR1 (L19): sc-73890, Santa Cruz
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sBiotechnology, Heidelberg, Germany). Positive (breast carcinoma)
and negative (PBS instead of primary antibody) controls were also
conducted. After washing with phosphate-buffered saline (PBS)
containing 0.1% Tween-20, sections were incubated with second-
ary antibody for 30min at room temperature (ImmPRESS
Universal Antibody Polymer Detection Kit, Vector Laboratories).
Antigen–antibody reaction was visualised using diaminobenzidine
chromogen and sections were counterstained with haematoxylin.
All slides were examined and scored by two independent
observers. The staining was scored as negative (¼0), or positive
with weak (¼1), moderate (¼2) and strong (¼3) intensity.
Statistical analysis
The statistical analysis was performed using SPSS software (SPSS
version 16.0, Chicago, IL, USA). The correlation between
methylation of each CpG-island and clinicopathological features
of CCA patients including gender, gross types and histological
grades, was analysed using w
2-test or Fisher’s exact test. The
correlation between methylation status and age at initial diagnosis
was analysed using Mann–Whitney U-test. The association of
methylation and overall survival time was determined using
Kaplan–Meier method by log-rank test or univariate analysis by
Cox regression. The association between MSP and pyrosequencing,
COBRA or protein expression was analysed using w
2-test. Two
sided Po0.05 was considered as statistically significant.
RESULTS
Frequency of CpG-island methylation and concurrent
methylation in cholangiocarcinoma
The CpG-island hypermethylation of 26 loci was investigated in
102 primary CCA and 29 matched adjacent normal tissues using
MSP (Figures 1 and 2). All bisulfite-treated DNA samples were
tested with Calponin-specific primer sets to demonstrate success-
ful bisulfite modification before MSP analysis (Teodoridis et al,
2005; Sriraksa et al, 2010). The CpG-islands with high frequency of
methylation in CCA included 14–3–3s, OPCML, SFRP1, HIC1,
PTEN and DcR1 (81.4, 72.5, 63.7, 38.2, 35.3 and 28.4%,
respectively). Moderately frequent methylation was found for
MINT25, p16, RASSF1A and BLU (15.7, 15.7, 14.7 and 10.8%,
respectively) and low frequency was observed for DAPK, CASP8,
FAS, MGMT and p73 in 1–10% of CCA. No methylation was
detected for APAF1, BRCA1, DcR2, DR4, DR5, FancF, GSTP1, p21,
SOCS3, Survivin and TMS1. Adjacent normal tissues showed no or
very low levels of methylation at all loci, with the exception of
14–3–3s for which a high frequency of methylation (75.9%) was
found in normal adjacent tissue, and therefore methylation data
for 14–3–3s has been excluded from subsequent analysis. After
excluding 14–3–3s, 91% (93 out of 102) of CCA samples were
methylated in at least one locus out of the 14 loci (OPCML, SFRP1,
HIC1, PTEN, DcR1, MINT25, p16, RASSF1A, BLU, DAPK, CASP8,
FAS, MGMT and p73).
We analysed the tumours for a methylation index (MI), which
was calculated from the ratio between the number of methylated
CpG-islands and the number of analysed CpG-islands (Gutierrez
et al, 2004). The average methylation index of CCA was
significantly higher than that in adjacent normal tissues (average
MI; 0.12 vs 0.02, Po0.001) as shown in Figure 3. Concordant
methylation in CCA was found between pairs of CpG-island
including OPCML and SFRP1 (P¼0.007), OPCML and HIC1
(o0.001), and HIC1 and PTEN (P¼0.002). No significant
association between other pairs of CpG-island was observed. In
addition, we also analysed the association of MI and clinicopatho-
logical data of CCA patients. However, no significant correlation of
clinical data and MI was observed.
OPCML
The highest methylation frequency was observed in 72.5% of CCA
for OPCML, whereas no methylation of this locus was revealed in
adjacent normal samples. In addition, methylation of OPCML was
found more frequently in less differentiated type (88%; 22 out of
25) than in the well-differentiated types of CCA (67.6%; 50 out of
74) (P¼0.047). To confirm the methylation detected by MSP, an
independent method of methylation analysis, COBRA, was used.
The correlation between MSP and COBRA results was analysed
using w
2-test and significant association with MSP was found at
OPCML by COBRA (80.0% of tested samples, P¼0.025). To
address whether methylation has effect on gene expression,
immunohistochemistry was performed to determine OPCML
protein expression in CCA samples. Low or no OPCML protein
expression was detected in CCA, 63% (58 out of 92) weakly
expressed OPCML and 26% (24 out of 92) exhibited no detectable
expression. Low-protein expression was found in 88% (59 out of
67) of OPCML-hypermethylated CCA, however, as the vast
majority of tumours (89%) had no or very low OPCML expression,
it was not feasible to statistically analyse the association between
expression and methylation.
DcR1
In the present study, DcR1 CpG island methylation was observed in
28.4% of CCA. Interestingly, patients with methylated DcR1
showed longer overall survival than those without (Median; 41.7
vs 21.7 weeks, P¼0.027), Figure 4. The significance of methylated
DcR1 on survival raised the question on the role of methylation
status of other TRAIL-related genes in CCA. To address this
question, we next analysed methylation of CpG islands at DcR2,
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Figure 1 Methylation profile of 26 CpG-islands in cholangiocarcinoma
and adjacent normal samples. Black and grey boxes represent positive and
negative methylation by MSP, respectively.
Methylation in cholangiocarcinoma
R Sriraksa et al
1315
British Journal of Cancer (2011) 104(8), 1313–1318 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
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these loci. To confirm the methylation detected by MSP, we
showed a significant correlation between MSP and pyrosequencing
in each individual CpG site of DcR1 and also in the average of the
four CpG sites examined. Moreover, a trend of correlation of
methylation in CpG1 with patient survival was observed (P¼0.08,
data not shown), similar to that of MSP. Low or no DcR1 protein
expression was detected in CCA, in which 54% (50 out of 92)
showed low-DcR1 expression and 23% (22 out of 92) displayed no
expression. Increased frequency of low-protein expression was
also observed in 77% (20 out of 26) of DcR1-hypermethylated
samples. In addition, low-DcR1 expression was observed in ID
type (100%; 11 out of 11), followed by MF (82.5%; 47 out of 57) and
PI types (58.3%; 14 out of 24) (P¼0.01).
DISCUSSION
In the present study, the majority of CCA (91%) shows aberrant
methylation in at least one locus, suggesting that DNA methylation
is a common event in CCA, which is in agreement with previous
reports (Lee et al, 2002; Yang et al, 2005). The high-methylation
frequency of 14–3–3s found in CCA and adjacent normal tissues
is similar to that observed in normal breast tissue and breast
cancer (Umbricht et al, 2001) suggesting that methylation of
14–3–3s is tissue specific regardless of pathological status. The
high-methylation frequency presented for CpG islands at OPCML,
SFRP1, HIC1, PTEN and DcR1 suggests that many signalling
pathways could be involved in the development and progression of
CCA, although does not demonstrate that all are drivers of
carcinogenesis. However, association of methylated OPCML and
DcR1 with patient clinicopathological data supports their role in
tumour progression. The tumour suppressor gene OPCML (Opioid
binding protein/cell adhesion molecule-like gene) belongs to the
IgLON family of immunoglobulin (Ig) domain containing glyco-
sylphosphatidylinositol (GPI)-anchored cell adhesion molecules
that are involved in cell adhesion and cell–cell recognition
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survival time of cholangiocarcinoma patients. Patients with methylated
DcR1 had longer overall survival time than those without (Kaplan–Meier
analysis using log-rank test, P¼0.027).
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s(McNamee et al, 2002; Sellar et al, 2003). In addition, OPCML has
been proposed as a stress- and p53-responsive gene, with the
response impaired when the promoter becomes hypermethylated.
Moreover, exogenous expression of OPCML in carcinoma cells
lacking its expression leads to dramatic growth inhibition
suggesting OPCML as a tumour suppressor (Sellar et al, 2003;
Cui et al, 2008). The OPCML hypermethylation has been reported
in several cancers for example, 33.3% of late stage ovarian cancer
(Teodoridis et al, 2005), 70% of hepatocellular carcinoma (Liu
et al, 2006a), 63.9% of invasive cervical cancer (Ye et al, 2008) and
57–100% of multiple carcinomas and lymphomas (Cui et al, 2008).
We are the first to report OPCML methylation in CCA with high
frequency (72.5%) with no methylation in normal adjacent tissue.
The previous studies have demonstrated that CCA with less
differentiation shows a poorer outcome and high incidence of
metastases than well differentiated tumours (Nakajima et al, 1988;
Nakanuma et al, 2000). The high incidence of OPCML methylation
in CCA and its association with less differentiation together with
its absence in normal tissue indicate that OPCML methylation
could be used as an epigenetic biomarker for molecular prognosis
and diagnosis of CCA.
The highly frequent methylation of SFRP1, HIC1 and PTEN
could lead to an increase in proliferation, inhibition of apoptosis
and promotion of survival advantage in CCA through increased
Wnt/b-catenin signal transduction through the impaired
p53-responsive pathway and activated PI3K and its downstream
effectors as previously reported in other cancers (Wales et al, 1995;
Finch et al, 1997; Melkonyan et al, 1997; Besson et al, 1999; Nicoll
et al, 2001; Sulis and Parsons, 2003; Chen et al, 2005; Manning and
Cantley, 2007; Takagi et al, 2008; Fleuriel et al, 2009).
The defect of programmed cell death through p53-dependent
pathway has been observed in CCA with mutational inactivation
(41.6%) and LOH of p53 (32%) as shown in our previous studies
together with p53 deacetylation because of HIC1 methylation
(38.2%) in this study. These phenomena impede p53 function,
which allows cells to bypass apoptosis and survive DNA damage
(Limpaiboon et al, 2002, 2004). It is surprising that death receptor-
induced apoptosis was rarely methylated. These findings indicate
the advantage for selective cancer treatment and good outcome in
CCA patients. The decoy receptors have been postulated to
account for TRAIL resistance as overexpression of DcR1 and/or
DcR2 prevent cancer cells from TRAIL-induced apoptosis.
Hypermethylation of DcR1 (28.4%), but not death receptors
(DR4 and DR5) and other TRAIL signalling-related genes (APAF1,
CASP8 and DcR2) in our study indicates the potential use of
recombinant TRAIL or TRAIL receptor agonistic monoclonal
antibodies as selective anti-tumour therapy in CCA. To overcome
TRAIL resistance that always happens, combined treatment with
standard chemotherapeutics can enhance TRAIL-induced apopto-
sis. Previous studies showed correlation of methylated DcR1 with
improved prognosis in malignant mesothelioma and prostate
cancer (Shivapurkar et al, 2004; Suzuki et al, 2006). As longer
overall survival was observed in methylated DcR1 patients, DcR1
methylation may be useful as a prognostic marker of CCA.
In conclusion, promoter hypermethylation has been observed in
many genes, which have important roles in carcinogenesis and
progression of liver fluke-related CCA. Further study is warranted
to validate the use of high-frequency methylated genes as potential
biomarkers for diagnosis, prognosis and prediction of CCA
patients. Moreover, tumour cells are significantly more sensitive
to TRAIL-induced apoptosis than normal cells, thus the use of
recombinant TRAIL or TRAIL receptor agonistic monoclonal
antibodies for selective treatment of CCA in combination with
chemotherapeutic drugs may improve patient survival.
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